Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine

• Status: Completed
• Trial end date: 1988-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and eliminated through the kidneys in HIV infected patients. Part II studies the effect of probenecid and quinine on the same aspects.

Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT needed for treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Probenecid; Quinine; Zidovudine

Criteria

Inclusion Criteria

Patients must:

• Have symptomatic HIV infection.

• Be taking zidovudine (AZT), 100 or 200 mg, 5 or 6 x/day.

Allowed:

• History of Pneumocystis carinii pneumonia (PCP).

• Advanced AIDS related complex (ARC).

• HIV antibody positive with an absolute CD4 lymphocyte count of < 200 cells/mm3 before study entry.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following conditions are excluded:

• Glucose-6-phosphate dehydrogenase deficiency.

• Allergy to sulfa drugs, probenecid, or quinine.

Concurrent Medication:

Excluded:

• Other drugs that might influence the metabolism or renal excretion of zidovudine (AZT).